-
D-Luciferin for Mechanistic Cancer BLI
2026-08-28
D-Luciferin is a firefly luciferase substrate that can connect transcriptional mechanism, intracellular ATP quantification, and longitudinal cancer imaging. This guide applies the molecule to assay design inspired by the FGF19–ELF4–FGFR4–SRC metastasis study, emphasizing interpretation, controls, and practical workflow decisions.
-
Abelmoschus manihot Polysaccharides in Liver Fibrosis
2026-08-27
This 2026 study identifies the AMPK/Nrf2/HO-1 pathway as a mechanistic link between Abelmoschus manihot polysaccharides, macrophage polarisation, hepatic stellate cell activation, and extracellular matrix remodelling. Using a CCl4-induced mouse model alongside macrophage and stellate-cell assays, the authors show that pathway inhibition with Compound C weakens the polysaccharide-associated antifibrotic response.
-
Hypoxia and Immunometabolism in Tumors
2026-08-27
The reference review explains how oxygen limitation and nutrient competition connect tumor metabolic reprogramming with immune dysfunction in the tumor microenvironment. Its main practical contribution is a mechanistic framework for interpreting hypoxia-inducible signaling, glucose-centered metabolism, and immunosuppressive cell states when designing tumor metabolism studies and therapeutic strategies.
-
AICAR Workflows for AMPK Metabolic Research
2026-08-26
AICAR provides a practical AMPK activation benchmark for studying energy metabolism, inflammatory signaling, and cellular stress. This workflow connects AICAR treatment to the TRPV1–AMPK–lipid droplet mechanism reported in hepatic fibrosis research, while highlighting controls and troubleshooting steps that improve interpretability.
-
Trelagliptin succinate in Adipocyte Research
2026-08-26
Trelagliptin succinate, also known as SYR-472 succinate, provides a practical bridge between DPP-4 enzyme inhibition and cell-based insulin-resistance assays. This workflow-centered guide shows how to connect glucose uptake, GLUT4 trafficking, adipokines, and PI3K/Akt signaling while controlling solvent, dose, and interpretation risks.
-
ATP Solution for mRNA-LNP Assay Design
2026-08-25
ATP Solution (100 mM) can serve as a controlled nucleotide and phosphate donor input across mRNA-LNP development workflows. This article connects ATP quality, reaction design, and the p21 mRNA-LNP bladder cancer study to practical assay decisions without treating a research reagent as a therapeutic claim.
-
Scalable EPSC-Derived EVs for Pulmonary Fibrosis
2026-08-25
Gong et al. developed a bioreactor-based platform that generates induced mesenchymal stromal cells from extended pluripotent stem cells and continuously harvests their extracellular vesicles. The study shows that these iMSC-EVs can be produced at high yield while retaining key features and antifibrotic activity comparable to primary MSC-EVs, providing a useful framework for translational EV manufacturing.
-
ATP Solution (100 mM): 5 Lab Scenarios
2026-08-24
A practical, scenario-based guide to using ATP Solution (100 mM), SKU K1043, in kinase, transcription, ligation, and phosphorylation workflows supporting cell viability and mRNA-LNP research. It separates ATP-dependent biochemical controls from direct cellular viability measurements and provides evidence-based handling recommendations.
-
LBP, AMPK–Mitophagy, and Muscle Atrophy
2026-08-24
The 2025 reference study identifies AMPK/PINK1/Parkin-mediated mitophagy as a mechanistic route by which Lycium barbarum polysaccharide may alleviate high-fat-diet-associated skeletal muscle atrophy. Its combined mouse and cell-model design links improved glucose–lipid handling with mitochondrial quality control, while inhibitor and Parkin-knockdown experiments strengthen the proposed pathway-level interpretation.
-
Firefly Luciferase mRNA: ARCA and 5-moUTP
2026-08-23
Firefly Luciferase mRNA (ARCA, 5-moUTP) is a 1,921-nucleotide, modified reporter transcript designed for robust luciferase expression. Its ARCA cap, 5-methoxyuridine modification, and approximately 100-nucleotide poly(A) tail support translation-focused gene expression assays, cell viability assays, and in vivo imaging workflows.
-
AZD1390: Mapping G4 Stress to ATM Response
2026-08-22
AZD1390 is a selective ATM kinase inhibitor for dissecting how G-quadruplex replication stress becomes checkpoint failure and radiation sensitivity. This article translates REV1–DHX36 findings into a practical assay framework for cancer research without conflating ATM inhibition with direct G4 repair disruption.
-
Vidarabine monohydrate: Applied Antiviral Workflows
2026-08-22
Build reproducible antiviral assays around Vidarabine monohydrate with solvent-aware dosing, time-of-addition experiments, and orthogonal DNA replication readouts. The workflow is especially useful for herpes simplex virus research and for separating viral DNA synthesis inhibition from nonspecific cytotoxicity.
-
AMPK, ULK1, and the Energy Stress Response
2026-08-21
The Nature Communications study challenges the prevailing view that AMPK universally promotes autophagy during glucose starvation. Its experiments show that AMPK suppresses ULK1-dependent autophagy initiation during acute energy stress while preserving autophagy machinery for recovery, revealing a context-dependent role in cellular survival.
-
NF 449: Reliable P2X1 Platelet Assays
2026-08-20
NF 449 (SKU B6716) is a highly potent purinergic receptor antagonist for resolving P2X1-dependent ATP signaling in platelet activation and aggregation studies. This scenario-driven guide connects receptor selectivity, practical handling, concentration design, data interpretation, and product-selection criteria to more defensible laboratory workflows.
-
NF 449 and P2X1 Receptor Antagonism
2026-08-20
The reference study established NF 449 as an exceptionally potent and subtype-selective purinergic receptor antagonist by profiling recombinant rat P2X homomers and heteromers. Its electrophysiological design provides a rigorous framework for distinguishing P2X1-mediated signaling from responses mediated by related ATP-gated ion channels, while also defining the limits of translating recombinant receptor data into platelet research.